Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy

The pathogenesis of rheumatoid arthritis: new insights from old clinical data?

(2012) Josef S. Smolen et al.   Nature Reviews Rheumatology

2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

(2012) Jasvinder A. Singh et al.   ARTHRITIS CARE & RESEARCH

Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries

(2011) K. Chatzidionysiou et al.   ANNALS OF THE RHEUMATIC DISEASES

BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis

(2011) M. Bukhari et al.   RHEUMATOLOGY

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

(2010) J. S. Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Management of nonresponse to rituximab in rheumatoid arthritis: Predictors and outcome of re-treatment

(2010) E. M. Vital et al.   ARTHRITIS AND RHEUMATISM

Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients

(2009) M. C. Genovese et al.   ANNALS OF THE RHEUMATIC DISEASES

Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis

(2009) Richa Mishra et al.   RHEUMATOLOGY INTERNATIONAL

Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study

(2008) M H Buch et al.   ANNALS OF THE RHEUMATIC DISEASES

Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease

(2008) N. Nishimoto et al.   BLOOD

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

(2008) Josef S Smolen et al.   LANCET